Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2002-10-25
2008-08-19
Sheikh, Humera N (Department: 1618)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S464000, C424S468000, C424S472000, C424S489000
Reexamination Certificate
active
07413751
ABSTRACT:
A method of treatment for hypertension and other disease states is described, which comprises the delivery of losartan in a gastric retained dosage form.
REFERENCES:
patent: 5007790 (1991-04-01), Shell
patent: 5138069 (1992-08-01), Carini et al.
patent: 5264447 (1993-11-01), Ohtawa
patent: 5266583 (1993-11-01), Ohtawa
patent: 5464854 (1995-11-01), DePadova et al.
patent: 5582837 (1996-12-01), Shell
patent: 5608075 (1997-03-01), Campbell et al.
patent: 5795904 (1998-08-01), Cohen et al.
patent: 5824696 (1998-10-01), Griswold et al.
patent: 5859258 (1999-01-01), Breen et al.
patent: 5872984 (1999-02-01), Berglund et al.
patent: 5952305 (1999-09-01), Pfeffer et al.
patent: 5972389 (1999-10-01), Shell et al.
patent: 5972990 (1999-10-01), Pfeffer et al.
patent: 5985915 (1999-11-01), Frangin et al.
patent: 6087386 (2000-07-01), Chen et al.
patent: 6093748 (2000-07-01), Ahluwalia et al.
patent: 6096772 (2000-08-01), Fändriks et al.
patent: 6103266 (2000-08-01), Tapolsky et al.
patent: 6110895 (2000-08-01), Rodgers et al.
patent: 6127370 (2000-10-01), Smith et al.
patent: 6139847 (2000-10-01), Chobanian et al.
patent: 6187340 (2001-02-01), Fukuta et al.
patent: 6191156 (2001-02-01), Kifor et al.
patent: 6201002 (2001-03-01), Beere et al.
patent: 6235766 (2001-05-01), Heitsch et al.
patent: 6248729 (2001-06-01), Coniglio et al.
patent: 6340475 (2002-01-01), Shell et al.
patent: 6451808 (2002-09-01), Cowles
patent: 6488962 (2002-12-01), Berner et al.
patent: 6669955 (2003-12-01), Chungi et al.
patent: 1251832 (2002-10-01), None
patent: WO 97/02032 (1997-01-01), None
patent: WO 97/21436 (1997-06-01), None
patent: WO 97/49392 (1997-12-01), None
patent: WO 98/55107 (1998-12-01), None
patent: WO 01/32217 (2001-05-01), None
patent: WO 01/56544 (2001-09-01), None
patent: WO 01/76573 (2001-10-01), None
patent: WO 02/096404 (2002-12-01), None
U.S. Appl. No. 09/425,491, Shell John W. et al., Not published.
U.S. Appl. No. 10/029,134, Berner et al., Not published.
U.S. Appl. No. 10/014,750, Berner et al., Not published.
U.S. Appl. No. 10/045,816, Berner et al., Not published.
U.S. Appl. No. 10/024,932, Berner et al., Not published.
U.S. Appl. No. 10/066,146, Lim et al., Not published.
U.S. Appl. No. 10/045,823, Shell et al., Not published.
U.S. Appl. No. 10/213,823, Berner et al., Not published.
U.S. Appl. No. 10/235,076, Markey et al., Not published.
U.S. Appl. No. 10/281,284, Berner et al., Not published.
U.S. Appl. No. 10/293,217, Berner et al., Not published.
Andersson et al., “Candesartan Cilexetil vs. Losartan”J. of Human Hypertension12: 419-422 (1998).
Aronow, “Treatment of Congestive Heart Failure in Older Person”JAGS45: 1252-1258 (1997).
Aronow, “The Elite Study: What are its Implications for the Drug Treatment of Heart Failure?”Drugs&Aging12(6): 423-428 (1998).
Awan et al., “Direct Selective Blockade of the Vascular Angiotensin II Receptors in Therapy for Hypertension and Severe Congestive Heart Failure”American Heart Journal131: 177-85 (1996).
Azizi et al., “Pharmacokinetic-Pharmacodynamic Interactions of Candesartan Cilexetil and Losartan”Journal of Hypertension17(4): 561-568 (1999).
Bauer et al., “The Angiotensin II Type 1 Receptor Antagonists”Arch. Intern Med.155: 1361-1368 (1995).
Beevers “Candesartan and Losartan: a Statement From the Editor”J. of Human Hypertension12: 419-422 (1998).
Belz et al., “Inhibition of Angiotensin II Pressor Response and Ex Vivo Angiotensin II Radioligand Binding by Candesartan Cilexetil and Losartan in Healthy Human Volunteers,”J. of Human Hypertension11 (Suppl. 2): S45-S47 (1997).
Brunner et al., “Angiotensin II Blockade Compared With Other Pharmacological Methods of Inhibiting the Renin-Angiotensin System,”J. of Hypertension11 (Suppl. 3): S53-S58 (1993).
Brunner et al., “Pharmacokinetic II receptor antagonists in normal volunteers,”Kidney International49 (Suppl. 55): S24-S29 (1996).
Bunt et al., “Candesartan vs. Losartan”J. of Human Hypertension12: 419-422 (1998).
Burnier et al., “Pharmacokinetic-Pharmacodynamic Relationships of Three Angiotensin II Receptor Antagonists in Normal Volunteers”Kidney International49 (Suppl. 55): S-24-S-29 (1996).
Burnier et al., “Comparative Antihypertensive Effects of Angiotensin II Receptor Antagonists”J. Amer. Soc. Of Nephrology10: S278-S282 (1999).
Burrell, “A Risk-Benefit Assessment of Losartan Potassium in the Treatment of Hypertension”Drug Safety16(1): 56-65 (1997).
Carr et al., “Losartan: First of a New Class of the Angiotensin Antagonists for the Management of Hypertension”J. Clin. Pharmacology36: 3-12 (1996).
Carson, “Rationale for the Use of Combination Angiotensin-Converting Enzyme Inhibitor Angiotensin II Receptor Blocker Therapy in Heart Failure”Am. Heart J.140: 361-366 (2000).
Christ “Human Plasma Protein Binding of the Angiotensin II Receptor Antagonist Losartan Potassium (Dup 753/ MK 954) and its Pharmacologically Active Metabolite EXP3174”J. Clin. Pharmacol.35:515-520 (1995).
Christ et al., “The Pharmacokinetics and Pharmacodynamics of the Angiotensin II Receptor Antagonist Losartan Potassium (DuP 753/MK 954) in the Dog”The J. of Pharm. and Experimental Therapeutics268(3): 1199-1205 (1994).
Chung et al., “Angiotensin II Receptor Pharmacology and AT1-receptor Blockers”Journal of Human Hypertension13 (Suppl. 1): S11-S20 (1999).
Coats, “Angiotensin Receptor Blockers—Finally the Evidence is Coming in: IDNT and RENAAL”Intl. J. of Cardiology79: 99-102 (2001).
Csajka et al., “Pharmacokinetic-Pharmacodynamic Profile of Angiotensin II Receptor Antagonists”Clin. Pharmacokinet.32(1): 1-29 (1997).
De Smet et al., “Effect of Multiple Doses of Losartan on the Pharmacokinetics of Single Doses of Digoxin in Healthy Volunteers”Brit. J. of Clin. Pharmacology40:571-575 (1995).
Doba et al., “Drugs, Heart Failure and Quality Of Life: What are we Achieving? What Should we be Trying to Achieve?”Drugs&Aging14(3):153-163 (1999).
Eberhardt et al., “Angiotensin II Receptor Blockade: An Innovative Approach to Cardiovascular Pharmacotherapy”J. Clin. Pharmacol.33: 1023-1038 (1993).
Elliott, “Angiotensin II Antagonists: Efficacy, Duration of Action, Comparison With Other Drugs”J. of Human Hypertension12: 271-274 (1998).
Ellis et al., “A New Class of Antihypertensive Therapy: Angiotensin II Receptor Antagonists”Pharmacotherapy16(5): 849-860 (1996).
Esmail et al., “Losartan as an Alternative to ACE Inhibitors in Patients with Renal Dysfunction”The Annals of Pharmacotherapy32: 1096-1098 (1998).
Fara, J. “Physiological Limitations: Gastric Emptying and Transit of Dosage Forms” in Rate Control in Drug Therapy, L.F. Prescott, et al., Eds., Churchill Livingstone, New York (1985).
Farthing et al., “Simple High-Performance Liquid Chromatography Method for Determination of Losartan and E-3174 Metabolite In Human Plasma, Urine and Dialysate”J. of Chromatography B704: 374-378 (1997).
Foote et al., “New Therapeutic Agents in the Management of Hypertension: Angiotensin II Receptor Antagonists and Renin Inhibitors”Annals of Pharmacotherapy27: 1495-1503 (1994).
Freudenthaler et al., “Dose-Dependent Effect of Angiotensin II on Human Erythropoietin Production”Eur. J. Physiol.439: 838-844 (2000).
Furtek et al., “Simultaneous Determination of a Novel Angiotensin II Receptor Blocking Agent, Losartan, and its Metabolite in Human Plasma and Urine by High-Performance Liquid Chromatography”J. of Chromatography573: 295-301 (1992).
Fyhrquist et al., “Role of Angiotensin II in Blood Pressure Regulation and in the Pathophysiology of Cardiovascular Disorders”J. of Human Hypertension9 (Suppl. 5):S19-S24 (1995).
Gabr et al., “Formulation and Evaluation of Buffered Floating Furosemide
Cumming K. Iain
Devane John
Gusler Gloria M.
Hou Sui Yuen Eddie
Depomed Inc.
King & Spalding LLP
Mohr Judy M
Sheikh Humera N
Simholi Paul B
LandOfFree
Methods of treatment using a gastric retained losartan dosage does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treatment using a gastric retained losartan dosage, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment using a gastric retained losartan dosage will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4015265